Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

December 26, 2020

Study Completion Date

December 26, 2020

Conditions
COVID-19
Interventions
DRUG

RhACE2 APN01

Patients will be treated with APN01 intravenously twice daily (BID).

DRUG

Physiological saline solution

Patients will be treated with placebo intravenously twice daily (BID).

Trial Locations (22)

2650

Hvidovre Hospital, Hvidovre

2730

Herlev Gentofte Hospital, Herlev

3400

Nordsjællands Hospital, Hillerød

111539

"State Healthcare Institution State Clinical Hspital № 15 named after O.M. Filatov", Moscow

123182

"Moscow State Budgetary Healthcare Institution City Clinical Hospital №52 of Health Department of Moscow", Moscow

129090

"Moscow State Budgetary Healthcare Institution N.V. Sklifosovsky Research Institute for Emergency Medicine of Health Department of Moscow", Moscow

150047

"Yaroslavl Regional Clinical Hospital for Military Veterans - International Centre for Gerontological Problems Healthy Ageing", Yaroslavl

170036

"State budgetary institution of Healthcare of Tver region Regional clinical hospital", Tver'

193312

Alexandrovskaya Hospital, Saint Petersburg

196600

Saint Petersburg SBHI City Hospital 38 named after N A Semashko, Pushkin

198205

Saint-Petersburg State Budget Healthcare Institution City Hospital 15, Saint Petersburg

214006

"Regional State Budgetary Healthcare Institution Clinical Hospital №1", Smolensk

390026

"Federal State Budgetary Educational Institution of Higher Education Ryazan State Medical University named after I.P. Pavlov HD RF", Ryazan

410054

"Federal State Budgetary Educational Institution of Higher Education Saratov State Medical University named after V.I. Razumovsky HD RF", Saratov

656045

"Regional State Budgetary Educational Institution Clinical Hospital № 5, Barnaul", Barnaul

Unknown

Medizinische Universität Innsbruck, Innsbruck

Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Vienna

Medizinische Universität Wien, Vienna

The National University Hospital, Rigshospitalet, Copenhagen

Universitätsklinikum Hamburg-Eppendorf, Hamburg

Klinikum rechts der Isar, Technische Universität München, München

CB2 0QQ

Cambridge University Hospitals NHS Trust/University of Cambridge, Cambridge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Apeiron Biologics

INDUSTRY

NCT04335136 - Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 | Biotech Hunter | Biotech Hunter